<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04226365</url>
  </required_header>
  <id_info>
    <org_study_id>2019-83</org_study_id>
    <nct_id>NCT04226365</nct_id>
  </id_info>
  <brief_title>Pediatric Concussion Outcomes</brief_title>
  <acronym>PeCon</acronym>
  <official_title>Treatment for Post-concussive Headache: A Randomized, Placebo-controlled, Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lancaster General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lancaster General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blinded trial in which subjects with a post&#xD;
      concussive headache meeting inclusion criterion will be assigned to one of two treatment&#xD;
      groups: placebo or nortriptyline. Each group will be evaluated at week 0 and again each week&#xD;
      for the next 4 weeks of treatment with a concussion survey that rates their symptoms. At the&#xD;
      end of 4 weeks the study will be unblinded. It is hypothesized that the addition of&#xD;
      nortriptyline to the standard headache treatments will result in more rapid decrease of&#xD;
      symptom score than with placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">August 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Concussive Symptom Inventory (PSCI) score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Post-Concussive Symptom Inventory (PSCI) score of 0-1 on the headache symptom, where the score ranges from 0 (absent) to 6 (severe). A score of 0 is optimal, while a score of 6 is not optimal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Concussion Post Syndrome</condition>
  <condition>Headaches Posttraumatic</condition>
  <condition>Mild Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg capsule once daily for 4 weeks of nortriptyline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10mg capsule once daily for 4 weeks of Thick-It filler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nortriptyline</intervention_name>
    <description>10mg capsule Nortryptyline</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10mg capsule Thick-It filler</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be eligible to participate in this study, an individual must meet all of the&#xD;
        following criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 13-18 years old&#xD;
&#xD;
          4. In good general health as evidenced by medical history and diagnosed with recent head&#xD;
             trauma meeting ICHD-3 criteria for acute posttraumatic headache with symptom onset &lt; 7&#xD;
             days from trauma&#xD;
&#xD;
          5. Ability to take oral medication and be willing to adhere to the medication regimen&#xD;
&#xD;
          6. No loss of consciousness OR loss of consciousness &lt;30 minutes&#xD;
&#xD;
          7. Headache symptoms persisting â‰¥4 weeks post trauma&#xD;
&#xD;
          8. Agreement to avoid over the counter supplements&#xD;
&#xD;
          9. Agreement to adhere to 3x weekly dosing of NSAIDs to avoid rebound headache from&#xD;
             overuse.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        An individual who meets any of the following criteria will be excluded from participation&#xD;
        in this study:&#xD;
&#xD;
          1. Focal neurological deficits following injury&#xD;
&#xD;
          2. Any abnormality on Computed Tomography (if obtained)&#xD;
&#xD;
          3. History of known neurological disorder (history of prior TBI, seizure disorder)&#xD;
&#xD;
          4. History of known psychiatric disease (ex. ADHD, anxiety, depression) given the&#xD;
             potential side effects of the study drug.&#xD;
&#xD;
          5. Current suicidal ideation as screened for on PHQ-A on intake&#xD;
&#xD;
          6. Current treatment with antidepressants&#xD;
&#xD;
          7. A personal history of Brugada syndrome&#xD;
&#xD;
          8. Known allergic reaction to nortriptyline&#xD;
&#xD;
          9. Current pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Health Sports Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laura DiPaolo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Health Sports Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn Medicine Lancaster General Health</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 9, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>concussion</keyword>
  <keyword>headache</keyword>
  <keyword>mild TBI</keyword>
  <keyword>post concussion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Post-Concussion Syndrome</mesh_term>
    <mesh_term>Post-Traumatic Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

